FCGR2B and lymphoma: Alterations in the FCGR2B gene are associated with diseases such as systemic lupus erythematosus and rheumatoid arthritis, and its upregulation reduces the sensitivity of lymphoma to rituximab (Lee et al., 2015; Meister et al., 2015; Kim et al., 2016).